About Us

Vector Laboratories develops, manufactures and markets labeling and detection reagents for immunohistochemistry, immunofluorescence, DNA/RNA and glycobiology. The company serves customers in disease and therapeutics research with tools that help them precisely visualize and study tissues and cells. A pioneer in a number of innovative technologies, Vector Laboratories has been providing a continuous stream of reliable tools for more than 40 years. With headquarters in Burlingame, California and a subsidiary in Peterborough, UK, the company maintains a network of more than 40 distributors across the globe. A privately held company, Vector Laboratories was acquired by Maravai LifeSciences in 2016.

Vector Labs Headquarters

40-Year History of Quality and Innovation

Vector Labs Building

1976

Vector Laboratories is founded

1980

Vector Labs first to commercialize avidin-biotin enzyme complex (VECTASTAIN® ABC kits)

Vectastain ABC Kits
Affinity of Avidin for Biotin

1981

S.M. Hsu published that the high affinity of avidin for biotin could be used to increase the stability of the enzyme antibody complex

1986

Vector Labs launches PHOTOPROBE® Biotin

photoprobe biotin
VECTASHIELD MountingMedia

1993

Vector Labs introduced first antifade mounting media for fluorescence (VECTASHIELD® Mounting Media)

1999

Vector Labs introduced a next-generation PAP pen conforming with environmental regulations (ImmEdge™ Pen)

Next-Generation PAP Pen
Mouse on Mouse (M.O.M.) Kit

2000

Vector Labs introduces M.O.M.® detection kits expanding the use of unconjugated mouse primary antibodies on mouse tissue sections.

2004

Vector Labs expanded antifade mounting media with hardening formulation (VECTASHIELD® HardSet™ Mounting Media)

VECTASHIELD hardset MountingMedia
detextion regents for antigens

2005

Vector Labs developed detection reagents enabling greater access to antigens within tissues and improving multiple antigen labeling (ImmPRESS® enzyme polymer)

2007

Vector Labs introduced proprietary substrates enabling multiplexing IHC (ImmPACT® HRP substrates)

ImmPACT Silo
Bloxall Silo

2011

Vector Labs introduced BLOXALL® Endogenous HRP and AP Blocking Solution

2014

Vector Labs introduced additional proprietary AP substrate (ImmPACT® Vector® Red substrate)

ImmPACT Vector Red Substrate
Maravai logo

2016

Strategic investment by Maravai LifeSciences

2017

Vector Labs introduces Vector® TrueVIEW™ Autofluorescent Quenching Kit

New Web Site
ISO 9001:2015 certification stamp

2018

Vector Labs achieves ISO 9001:2015 certification

Vector Labs introduces VECTASHIELD® Vibrance Antifade Mounting Media

Vectashield Vibrance Antifade Mounting Media

Company Information

Year Founded:
1976
Number of Employees:
50+
Facilities:
Headquarters, R&D and manufacturing in Burlingame, California USA, subsidiary in Peterborough, UK
Number of Products:
600+
Leading Product Groups:
VECTASTAIN® ABC Kits (avidin biotin systems)
ImmPRESS® Polymer Detection Reagents
M.O.M.® Mouse on Mouse Immunodetection Kits
Enzyme substrates
VECTASHIELD® Antifade Mounting Media
VectaCell™ Live Cell Imaging Reagents and Stains
Secondary fluorescent antibody conjugates
Key Disciplines Served:
Immunohistochemistry
Immunofluorescence
Glycobiology
Immunocytochemistry
Live Cell Imaging
Citations in Scientific Papers:
300,000 +
Trademarks:
ABC-AmP, Animal-Free Blocker, BLOXALL, DuoLuX, Elite, EndTag, ImmEdge, ImmPACT, ImmPRESS, ImmPrint, M.O.M., NeuroBiotin, PHOTOPROBE, QuantTag, VECTABOND, VectaCell, VectaMount, VECTASHIELD, VECTASHIELD HardSet, VECTASTAIN, Vector, Vector Black, Vector Blue, Vector NovaRED, Vector Red
Management:
Eric Tardiff, President
Eric brings over 20 years of experience in investment banking, corporate development and strategy, and operations management focusing on medical devices, diagnostics and life sciences. Prior to founding Maravai LifeSciences, Eric led corporate development and corporate strategy at Gen-Probe leading up to its acquisition by Hologic. Eric began his career as an investment banker executing mergers and acquisitions for Merrill Lynch, Piper Jaffray and Morgan Stanley. Throughout his banking career, Eric centered his attention on medical device companies, with a particular focus on the life sciences tools and diagnostics segments.

David Weber, Vice President and Chief Commercial Officer
David comes to Maravai LifeSciences with over 35 years of experience in life sciences industry commercial leadership and general management. David is responsible for all marketing, sales, product development, commercial strategy, service, and support for all Maravai LifeSciences portfolio companies. Prior to joining Maravai LifeSciences, David served as Executive Vice President and Chief Commercial Officer for Affymetrix leading up to its acquisition by Thermo Fisher Scientific. Earlier in his career, David held a variety of commercial leadership roles in life science companies including Amersham Biosciences (GE Healthcare), Eksigent Technologies, Cyntellect, Stratagene, and The Linus Group.

Harjit Kullar, Vice President of Marketing
Harjit comes to Maravai LifeSciences with over 15 years of experience in sales and marketing in the life sciences and diagnostics industries, most recently holding the position of Vice President of Marketing at Transgenomic. Earlier in his career, Harjit held a variety of commercial leadership roles in life science companies including Bio-Rad Laboratories, Thermo Fisher Scientific, Life Technologies, LifeSpan BioSciences and Abcam. Harjit received a BSc in Biochemistry & Pharmacology from University of Southampton, a Ph.D. in Cancer Biology from University of Birmingham and an MBA from University of Cambridge.
Contacts for the Media:
Jennifer Dahlgren, Dahlgren Communications
(530) 263-6817
[email protected]

David Weber, Chief Commercial Officer
Maravai LifeSciences
(650) 697-3600
[email protected]